I think, again, it's collaborative: Mr. Brown asked about other countries, and I just want to emphasize that there are, of course, many other countries doing work. We are always looking at collaborations. I'm going to a meeting next week in Montreal that is trying to bring together German and British medical research council people, looking at imaging neurodegeneration, together with Canadian. We bring in people from many countries for our own studies.
So funding for those collaborative things, for networks across the country, and funding for teams, are the biggest priorities. As to the specifics of what they do, it will be genetic research, genomic-based research, imaging research—a self-serving response—and, I would say, cell death biomarker.
I was very glad that Michael brought up the example of biomarkers, both fluid and imaging function in that role, mechanisms on cell death, pathways. Canada has strengths in all of these, but it's difficult to combine them all in one centre. We could either expand the centres or enhance collaboration between existing centres, with infrastructure to handle the information, because it's almost impossible to do, otherwise.